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Purpose or Objective: The purpose of this study was to 
investigate the effect of the modeling of the treatment table 
top on the agreement between calculations and 
measurements on the Delta4 phantom (Scandidos). Also, the 
effect of the most suitable way to determine the daily 
correction factor was investigated. 
 
Material and Methods: Two of our linear accelerators are 
equipped with the standard Elekta iBeam evo carbon fiber 
table top. In our treatment planning system, Pinnacle v9.0 
(Philips), the table top is modeled as a slab with dimensions 
equal to the width and height of the table top and with a 
density of 0.25 g/cm³. 
We extended the axial dimensions of the artificial CT-image 
set of the Delta4 phantom provided by Scandidos from 25 x 
25 cm² to 50 x 50 cm² by a home-made program written in 
java. This allows us to place the table top model below the 
phantom at the real distance, ie 7 cm. 15 IMRT plans for 
breast cancer were recalculated twice, once on the CT-
images of the Delta4 phantom provided by Scandidos and a 
second time on the extended CT-images with the table top 
model included. All plans consist of 5 to 6 beams (87 in total) 
from which 1 to 2 beams go through the table (23 in total). 
The plans were exported to the Delta4 software and 
measured. In case no table top model was included in the 
calculations, a daily correction factor based on the average 
of 4 beams (gantry angles of 0°, 90°, 180° and 270°) was 
applied. When the table top model was included, a daily 
correction factor based on 1 beam (gantry angle of 0°) was 
applied. A gamma criterion of 3%/3mm was used. Statistical 
analysis was done by paired t-tests. A p-value < 0.05 was 
considered as statistically significant. 
 
Results: Without the use of daily correction factors, the 
mean pass rate for the overall treatment plans was 
respectively 90.7% (±6.9 SD) and 95.2% (±3.0 SD) without and 
with the table top model applied. This difference is 
significant with p = 0.01. In the first group 4 out of 15 pass 
rates were > 95%, whereas in the second group this is 9 out of 
15. With the use of the proper daily correction factors, this 
increases to respectively 98.6% (±1.2 SD) and 99.1% (±0.9 SD). 
This difference is also significant with p = 0.04. In both 
groups, all pass rates were > 95%. 
For individual beams going through the table top, the mean 
pass rate was respectively 90.8% (±9.9 SD) and 99.0% (±1.9 
SD) without and with the table top model applied and 
without the use of daily correction factors (p = 0.0001). In 
the first group 10 out of 23 pass rates were > 95%, whereas in 
the second group this is 22 out of 23. With the use of the 
proper daily correction factors, this increases to respectively 
99.0% (±1.6 SD) and 99.9% (±0.4 SD) (p = 0.01). In the first 
group 22 out of 23 pass rates were > 95% and in the second 
group all pass rates were > 95%. 
 
Conclusion: The table top modeling results in a better 
agreement between measurements and calculations, both for 
total plans and individual beams. This agreement improves 
when proper correction factors are applied. 
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Purpose or Objective: In-vivo dose verification is the last 
step of a quality assurance procedure to ensure that the dose 
delivered during treatment is in agreement with the 
prescribed one.This work reports the in-vivo dosimetry (IVD) 
results obtained by the SOFTDISO software (Best Medical 
Italy) during VMAT prostate cancer treatments. 
 
Material and Methods: SOFTDISO is based on a method 
developed by a cooperation between INFN and UCSC. It 
reconstructs in quasi-real time (a few seconds at the end of 
the fraction therapy) (i) the dose at the isocenter (Diso) in 
the patient from the transit signal acquired by the EPID and 
(ii) the comparison between EPID images obtained during the 
fractions of the therapy. In particular for each beam and 
fraction, the R ratios between the dose reconstructed at the 
isocenter point, Diso, in single-arc (179-181°) VMAT plans for 
prostate targets and the dose calculated by the TPS, 
Diso,TPS (generally about 2 Gy for fraction) obtained by 
Oncentra Masterplan, were computed. The acceptance 
criteria was: 0.95≤R≤1.05. Moreover the γ-analysis (2%-2mm) 
between portal images supplied useful index about the beam 
delivery reproducibility with the Pγ<1>95% and γ mean<0.4. 
15 patients with prostate cancer were treated with 6 MV 
photon beam delivered by an Elekta Synergy Agility (Elekta, 
Crawley). Our protocol required, for each patient, the IVD in 
the first three treatment sessions after a CBCT based set-up 
correction and the IVD test once weekly afterwards for the 
rest of the treatment course when the CBCT scan was not 
acquired. 
 
Results: The IVD procedure supplied 105 tests and the 
average R was equal to 1.003 ± 0.028 (1SD), in a range 
between 0.949 and 1.058. The global R value for each single 
patient was well-within the 5% tolerance level. The γ-analysis 
between EPID images supplied Pγ<1≥97% in 80% of the tests. 
20% of the tests supplied 93% ≤P γ<1<95% due to small setup 
variations as verified by the CBCT required at the end of the 
fraction therapy. 
 
Conclusion: The IVD results supported the protocol about the 
CBCT carried out in the first three treatment sessions of the 
VMAT prostate cancer treatment. The facility of the real time 
test supplied by SOFTDISO allows a CBCT scan requirement 
after the daily-fraction that supplies IVD off tolerance level. 
The authors intend to apply this procedure to estimate 
protocols about the use of the CBCT scans for other 
pathologies as the head-neck tumors where heavy dose 
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Purpose or Objective: The study was aimed to check 
radiotherapy treatment accuracy and definition of action 
levels during implementation of in vivo dosimetry for 
treatment pelvic cancer patients as a part of quality 
assurance program. 
 
Material and Methods: Calibration and corrections factors for 
in vivo entrance dose measurements for n-type Isorad 
semiconductor diodes for photon energy of 15 MV were 
determined as per recommendations published by European 
Society for Radiotherapy and Oncology (ESTRO) Booklet No.5. 
The pelvic cancer patients for in vivo measurements have 
been divided into groups, according to radiation techique 
used, in order to investigate and detect the groups for which 
the uncertainty was larger or for which a systematic error 
occurred. Initial tolerance/action levels for all groups were 
set at level of 5 %. 
 
Results: In this study, entrance dose measurements were 
performed for total 185 treatment fields, of 95 pelvic cancer 
patients over one year period. In 6 (6%) out of 95 patients, in 
vivo measurements exceeded the tolerances. The mean value 
and the standard deviation for different groups were: Rectum 
and gynecology (four field box): 0.6%±3.07%(1SD), Prostate 
(five fields with wedges): +1.0%±2.22%(1SD). All pelvic 
measurements: +0.77%±2.79%(1SD). Larger standard deviation 
was shown for four field box cases because two large errors 
were noticed. After the corrections, in vivo dosimetry was 
repeated in both cases and the results were within the 
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tolerance levels and mean value and standard deviation four 
field box cases were +0.68%±2.43%(1SD). 
 
Conclusion: It was noticed that standard deviation for both 
patient groups was similar and that initial tolerance/action 
levels for pelvic cases were substantial. Also, the five fields 
technique with wedges showed good results due to uniform 
directional response around diode axis. Within one year after 
implementation, in vivo dosimetry has revealed and 
prevented 6 cases of inaccurate treatment. In our 
experience, systematic in vivo dosimetry proved to be a very 
useful tool for quality assurance of a patient plan and 
treatment, both in detecting systematic errors and for 
estimating the accuracy of radiotherapy treatment delivery. 
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Purpose or Objective: Brachytherapy HDR treatments are 
performed according to the plans calculated with the 
computerized treatment planning systems. The source 
positions and dwell times are established to produce required 
dose distributions. However, in general, the treatment plans 
are not verified. A phantom for such dose distribution 
verification is proposed to be used with the ArcCHECK 
system. 
 
Material and Methods: The ArcCHECK detector array and the 
SNC Patient software were designed by Sun Nuclear to verify 
dose distributions in the IMRT and VMAT external beam 
therapy. It is a cylindrical tissue-equivalent phantom, 
containing 3D detector array, consisting of 1386 SunPoint 
diodes. The detectors are located helically along the cylinder 
with the external diameter of 21 cm. We believe that the 
ArcCHECK phantom could also be used to verify the 
brachytherapy dose calculations. For this purpose a special 
additional part of PMMA, a Brachyplug, was designed and 
manufactured. The Brachyplug is a special cylinder installed 
inside the ArcCHECK in which it is possible to place 
dosimetric films or ionization chambers. The phantom has a 
number of through holes, where the HDR catheters can be 
placed into which the Ir-192 stepping source may enter. A 
special brachytherapy plan was created using the Ocentra 
MasterPlan planning system with 4 source positions in order 
to create evenly distributed dose over the detectors of the 
ArcCHECK array. In order to check the amount of dose which 
could be absorbed by the electronics of the ArcCHECK system 
the doses at the relevant distance were measured with the 
PTW dosimeter and a Farmer type 30013 ionization chamber 
placed in PTW RW3 plate phantom under the Brachyplug. The 
measurements were carried out with and without a shield, a 
8 cm thick Wood alloy plug, designed in order to protect the 
electronic control unit of the ArcCHECK from irradiation. 
After that the dose distribution for the planned source 
positions was measured with ArcCHECK device with 8 cm 
thick Wood alloy plug and Brachyplug placed inside the 
ArcCHECK cylinder. 
 
Results: Measurements of irradiation according to the 
prepared plan indicate that when the ArcCHECK detectors 
obtain the dose of 1 Gy the total dose which could reach the 
ArcCHECK electronics is 12.7 cGy. Such dose is acceptable 
and similar to the dose in a case of teletherapy. The 
ArcCHECK allowed for detecting and displaing in the SNC 
Patient software the HDR brachytherapy irradiation 
distributions. 
 
Conclusion: The ArcCHECK device may be potentially used 
for pretreatment verification of dose distributions in 
brachytherapy. This would require the development of proper 
energy calibration procedure for the ArcCHECK detectors and 
the SNC Patient software update. The Brachyplug phantom 
will be used for further research on verification of clinical 
treatment plans in brachytherapy. 
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Purpose or Objective: The IQM is an innovative wedge 
shaped transmission ion chamber which is mounted below the 
front face of a Linac head. It monitors the total radiation 
fluence coming from the treatment head (see figure). It is 
currently undergoing Beta-testing to monitor and verify the 
delivery of individual treatment fields in real-time. Its 
potential as a tool for Linac quality control measurements is 
also being investigated. 
 
Material and Methods: Over an 11 month period a series of 
QC and clinical prescriptions were delivered multiple times to 
the IQM mounted on an Elekta VersaHD Linac, to evaluate its 
sensitivity to potential clinical errors and its long-term 




IQM mounted on Linac, with schematic of detector design  
Results: The device proved reliable over the testing period. 
It’s stability and reproducibility are shown in the table. 
Measurements showed that MLC/Jaw mis-calibrations of 2mm 
could be identified, as could 2% errors in MU. A change of 
energy from 6MV to 10MV gave a difference in IQM signal of 
6% for conformal and ‘step and shoot’ IMRT, and of 2-4% for 
VMAT deliveries. Seventeen similar VMAT head and neck 
plans each demonstrated a unique IQM signal vs control point 
pattern, potentially allowing an incorrect plan, or ‘plan of 
the day’ to be identified after only 40 degrees of the arc. 
The IQM was able to identify clinically significant flatness, 
symmetry and output errors on the Linac. 
Modality Beam Description Standard Deviation 
Static field 10x10cm @6MV 0.7% 
Static field 4x4cm @6MV 1.0% 
Conformal Arc 10x10cm @6MV 0.8% 
IMRT Step & Shoot @6MV &10MV 0.7% 
Simple VMAT Prostate VMAT @10MV 0.8% 
Complex VMAT Head and Neck VMAT @6MV 1.1% 
Variation in IQM signal over 11 months for different 
modalities  
 
Conclusion: Although the IQM is still under development it 
can identify a number of clinically significant potential errors 
in treatment delivery. It is easy to use ‘on set’ and has 
proved stable and reliable. It has the potential for use as a 
